Q: Can we just spend a couple of minutes on COVID 19? Is AstraZeneca engaged in your challenge study model?
Unfortunately, we are precluded from talking about anybody, but I would say, bear with us until early September and a lot more might be revealed, and people might be very pleasantly surprised as to who and what is in. But the best way to look at it is that some of the big pharma companies won’t bother with the challenge study, they’re rushing out, trying to do a phase 3. Most of them are talking to see how quickly we can do a challenge study, so that’s where we are. I think we will have way more orders potentially than we could ever supply, so we’ve been picking and choosing. We’re trying to get between 8 and 10 million per study, and if we could get 8 or 10 within the next 12 months, we would be very happy.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).